Department of Experimental Oncology, European Institute of Oncology IRCCS, 20141Milan, Italy.
Departments of Medicine, Microbiology, Immunology & Infectious Diseases, and Pathology & Laboratory Medicine, Synder Institute for Chronic Diseases and O'Brien Institute for Public Health, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, Canada.
Epidemiol Infect. 2024 Nov 12;152:e138. doi: 10.1017/S0950268824001481.
The extent to which the oro-faecal route contributes to the transmission of SARS-CoV-2 is not established.We systematically reviewed the evidence on the presence of infectious SARS-CoV-2 in faeces and other gastrointestinal sources by examining studies that used viral culture to investigate the presence of replication-competent virus in these samples. We conducted searches in the WHO COVID-19 Database, LitCovid, medRxiv, and Google Scholar for SARS-CoV-2 using keywords and associated synonyms, with a search date up to 28 November 2023.We included 13 studies involving 229 COVID-19 subjects - providing 308 faecal or rectal swab SARS-CoV2 reverse transcription-polymerase chain reaction (RT-PCR)-positive samples tested with viral culture. The methods used for viral culture across the studies were heterogeneous. Three studies (two cohorts and one case series) reported observing replication-competent SARS-CoV-2 confirmed by quantitative RT-PCR (qPCR) and whole-genome sequencing, and qPCR including appropriate cycle threshold changes. Overall, six (1.9%) of 308 faecal samples subjected to cell culture showed replication-competent virus. One study found replication-competent samples from one immunocompromised patient. No studies were identified demonstrating direct evidence of oro-faecal transmission to humans.Our review found a relatively low frequency of replication-competent SARS-CoV-2 in faecal and other gastrointestinal sources. Although it is biologically plausible, more research is needed using standardized cell culture methods, control groups, adequate follow-up, and robust epidemiologic methods, including whether secondary infections occurred, to determine the role of the oro-faecal route in the transmission of SARS-CoV-2.
肠道-口途径在 SARS-CoV-2 传播中的作用程度尚未确定。我们通过检查使用病毒培养来研究这些样本中复制型病毒存在的研究,系统地回顾了粪便和其他胃肠道来源中存在传染性 SARS-CoV-2 的证据。我们使用关键字和相关同义词在世界卫生组织 COVID-19 数据库、LitCovid、medRxiv 和 Google Scholar 中对 SARS-CoV-2 进行了搜索,搜索日期截至 2023 年 11 月 28 日。我们纳入了 13 项涉及 229 名 COVID-19 受试者的研究-提供了 308 个粪便或直肠拭子 SARS-CoV2 逆转录-聚合酶链反应(RT-PCR)阳性样本,用病毒培养进行了测试。研究中使用的病毒培养方法存在异质性。三项研究(两项队列研究和一项病例系列研究)报告观察到复制型 SARS-CoV-2 通过定量 RT-PCR(qPCR)和全基因组测序证实,以及包括适当循环阈值变化的 qPCR。总体而言,308 个接受细胞培养的粪便样本中,有 6 个(1.9%)显示出复制型病毒。一项研究发现了来自一名免疫功能低下患者的复制型样本。没有研究证明直接证据表明肠道-口途径向人类传播。我们的综述发现,粪便和其他胃肠道来源中具有复制型 SARS-CoV-2 的频率相对较低。尽管从生物学角度来看是合理的,但需要使用标准化的细胞培养方法、对照组、充分的随访和稳健的流行病学方法进行更多研究,包括是否发生继发感染,以确定肠道-口途径在 SARS-CoV-2 传播中的作用。
Cochrane Database Syst Rev. 2024-12-16
Cochrane Database Syst Rev. 2022-11-17
Cochrane Database Syst Rev. 2024-10-14
Cochrane Database Syst Rev. 2022-7-22
Cochrane Database Syst Rev. 2023-1-30
Cochrane Database Syst Rev. 2022-5-20
Cochrane Database Syst Rev. 2022-1-17
Cochrane Database Syst Rev. 2022-5-6
Cochrane Database Syst Rev. 2022-5-16
Microorganisms. 2022-12-22
Epidemiol Infect. 2021-10-5